GlassScriptPhysician profile
Kyle A Duke
NPI 1083018550
$471.22
in general payments reported to CMS, 2019-2025
11 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $332 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $129.95 | 2024-2025 | Azstarys |
| Bioxcel Therapeutics, INC. | $82.90 | 2024 | Igalmi |
| Otsuka America Pharmaceutical, INC. | $57.35 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Almatica Pharma LLC | $36.69 | 2024-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $32.77 | 2024-2025 | Austedo Xr, Uzedy |
| Noven Therapeutics, LLC | $31.45 | 2024 | Secuado, Xelstrym |
| Sage Therapeutics, LLC | $29.04 | 2025 | Zurzuvae |
| Alkermes, INC. | $21.13 | 2025 | Aristada, Lybalvi |
| Tris Pharma INC | $19.52 | 2024 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $15.54 | 2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $14.88 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.